Relmada’s major depression drug shows PhIII promise in a fresh batch of patients
Relmada Therapeutics’ once-daily REL-1017 has shown positive data in major depressive disorder (MDD) from a registrational Phase III trial, a year after an unexpected late-stage failure.
The open-label study enrolled 204 patients who had not previously received REL-1017, an NMDA receptor channel blocker. The study’s total enrollment figure to date is 627, which includes patients who had rolled over from previous placebo-controlled trials of REL-1017, one of which had failed due to what the company described as a surprisingly strong placebo effect.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
